EquityZen Growth Technology Fund LLC - Series 2061
Raised
$2M
Investors
65
Min Invest
$8,362
AltStreet Analysis
·Generated from EDGAR primary sources
EquityZen Growth Technology Fund LLC - Series 2061 is a Delaware pooled investment fund vehicle that raised $2.4M from 65 investors under Rule 506(b) and Section 3(c)(1) exemptions, with an $8K minimum investment. Filed March 11, 2025 by EquityZen Advisors and Phil Haslett, this is part of EquityZen's platform of 1,889 pre-IPO investment entities.
This pre-IPO fund uses the standard 506(b)/3(c)(1) exemption pattern typical of private fund platforms, with an $8K minimum investment positioning it as retail-accessible compared to institutional minimums. The investor count (65) and total raise reflect EquityZen's model of pooling smaller checks to access late-stage private company equity.
Data Flags
EDGAR Filing Data
Form D — Primary Source
View on SEC.govRelated Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
EquityZen Advisors LLC
Executive Officer, Director · New York, NY
Phil Haslett
Executive Officer, Director · New York, NY
Is this your offering?
Claim this profile to add contact information, team members, LinkedIn profiles, fund history, and additional financial data. EDGAR-sourced data and AltStreet analysis cannot be edited, but corrections can be requested for verifiable inaccuracies.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.
